To elucidate the in vivo relevance of IL-6-mediated impairment of NKp30 expression in NSCLC, our in vitro simulations—based on established models of hypoxia and ER stress—demonstrate that elevated IL-6 levels directly suppress NKp30 on NK cells. This evidence concerns the gene IL6 and non-small cell lung carcinoma.